Ayranci Ferhat, Gungormus Metin, Omezli Mehmet Melih, Gundogdu Betul
Department of Oral Maxillofacial Surgery, Faculty of Dentistry, Ordu University, Ordu, Turkey.
Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Gaziantep University, Gaziantep, Turkey.
Iran Red Crescent Med J. 2015 Dec 27;17(12):e33569. doi: 10.5812/ircmj.33569. eCollection 2015 Dec.
Increasing sinus pneumatization and the accompanying alveolar bone resorption complicate dental implant placement. This problem can be overcome today by raising the maxillary sinus floor with graft materials. Bisphosphonates are commonly used to accelerate the recovery of the graft materials and to prevent resorption.
The purpose of this study is to investigate whether systemic administration of a bisphosphonate (alendronate) would improve new bone formation and reduce fibrous tissue formation over a 6-week follow-up in rabbits treated with two different grafting materials for maxillary sinus floor augmentation.
This experimental animal study was conducted at the Experimental Medical Application and Research Center at Erzurum/ Turkey. Twelve New Zealand rabbits, each weighing between 2.7 and 3.3 kg, were used. Twenty-four maxillary sinus floor elevation operations were performed, two on each animal (n = 24). Each elevation was repaired with either deproteinized bovine bone (xenograft) or autogenous bone graft obtained from the iliac crest. Both groups were divided into 2 subgroups: saline-treated and alendronate-treated. All groups underwent the same surgical procedures and evaluation, and were sacrificed at the 6th postoperative week. Sinuses augmented with deproteinized bovine bone (xenograft) and autogenous bone graft were examined histopathologically and histomorphometrically.
At 6 weeks, the bone area was significantly larger in the Xenograft-Alendronate group (33.0% ± 5.0%) than in the Xenograft-Saline group (20.8% ± 4.9%) and the bone area was significantly larger in the Autogenous-Alendronate group (43.3% ± 3.8%) than in the Autogenous-Saline group (37.5% ± 6.6%) (P = 0.001). The histomorphometric and histopathological results consistently showed that alendronate stimulated bone formation and reduced fibrous tissue formation in maxillary sinus augmentation grafts, especially in the deproteinized bovine bone group (xenograft).
Alendronate may be considered a therapeutic option for improving the bone formation process and reducing resorption in different bone grafting procedures. Further detailed studies should focus on dosage and time-dependent effects of alendronate on bone remodeling.
鼻窦气化增加以及随之而来的牙槽骨吸收使牙种植体植入变得复杂。如今,通过使用移植材料抬高上颌窦底可克服这一问题。双膦酸盐常用于加速移植材料的恢复并防止吸收。
本研究的目的是调查在接受两种不同上颌窦底提升移植材料治疗的兔子中,全身给予双膦酸盐(阿仑膦酸盐)是否会在6周的随访期内改善新骨形成并减少纤维组织形成。
本实验动物研究在土耳其埃尔祖鲁姆的实验医学应用与研究中心进行。使用了12只新西兰兔,每只体重在2.7至3.3千克之间。进行了24次上颌窦底提升手术,每只动物进行两次(n = 24)。每次提升均用脱蛋白牛骨(异种移植物)或取自髂嵴的自体骨移植修复。两组均分为两个亚组:生理盐水治疗组和阿仑膦酸盐治疗组。所有组均接受相同的手术程序和评估,并在术后第6周处死。对用脱蛋白牛骨(异种移植物)和自体骨移植增大的鼻窦进行组织病理学和组织形态计量学检查。
6周时,异种移植物 - 阿仑膦酸盐组的骨面积(33.0% ± 5.0%)显著大于异种移植物 - 生理盐水组(20.8% ± 4.9%),自体骨 - 阿仑膦酸盐组的骨面积(43.3% ± 3.8%)显著大于自体骨 - 生理盐水组(37.5% ± 6.6%)(P = 0.001)。组织形态计量学和组织病理学结果一致表明,阿仑膦酸盐刺激上颌窦增大移植中的骨形成并减少纤维组织形成,尤其是在脱蛋白牛骨组(异种移植物)中。
阿仑膦酸盐可被视为改善不同骨移植手术中骨形成过程和减少吸收的一种治疗选择。进一步的详细研究应关注阿仑膦酸盐对骨重塑的剂量和时间依赖性影响。